Evidence map›Paper›PMID 40948517›Full record

ArticleAmerican journal of cancer research2025

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.

Lori A Leslie, John H Baird, Ian W Flinn, Michael Tees, Daanish Hoda, Abhinav Deol, Patricia Young, Brian McClune, Indumathy Varadarajan, James Essell and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lori A LeslieJohn Theurer Cancer Center, Hackensack Meridian Health Hackensack, NJ, USA.
John H BairdDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center Duarte, CA, USA.
Ian W FlinnCentennial Center for Blood Cancers Clinic, Tennessee Oncology Nashville, TN, USA.
Michael TeesColorado Blood Cancer Institute/Sarah Cannon Research Institute Denver, CO, USA.
Daanish HodaIntermountain Health, LDS Hospital Salt Lake City, UT, USA.
Abhinav DeolKarmanos Cancer Institute Detroit, MI, USA.
Patricia YoungSanta Monica Cancer Care, UCLA Health Los Angeles, CA, USA.
Brian McCluneDepartment of Internal Medicine, University of Utah School of Medicine, Huntsman Cancer Institute Salt Lake City, UT, USA.
Indumathy VaradarajanUVA Health Charlottesville, VA, USA.
James EssellOncology Hematology Care, Sarah Cannon Research Institute Cincinnati, OH, USA.
Suzanne FanningPrisma Health Greenville, SC, USA.
Gary SimmonsVirginia Oncology Associates Norfolk, VA, USA.
William ClarkDepartment of Internal Medicine, Virginia Commonwealth University Richmond, VA, USA.
Aaron P RapoportUniversity of Maryland Greenebaum Comprehensive Cancer Center Baltimore, MD, USA.
Tulio E RodriguezDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center Chicago Zion, IL, USA.
Joshua N WintersKite, a Gilead Company Santa Monica, CA, USA.
Madison DavisKite, a Gilead Company Santa Monica, CA, USA.
Harry M MiaoKite, a Gilead Company Santa Monica, CA, USA.
Markqayne RayKite, a Gilead Company Santa Monica, CA, USA.
Xiang FangKite, a Gilead Company Santa Monica, CA, USA.
Jenny J KimKite, a Gilead Company Santa Monica, CA, USA.
Olalekan O OluwoleDepartment of Medicine, Vanderbilt University Medical Center Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ZUMA-24 is a Phase 2, open-label, multicenter study that investigated safety and efficacy of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, administered in the outpatient setting to patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) with ≥1 prior lines of therapy. Patients underwent leukapheresis and received lymphodepleting chemotherapy, axi-cel infusion (2×10

Indexed as

CAR-Tchimeric antigen receptorclinical trialLarge B-cell lymphomaoutpatientphase 2

Identifiers

PMID40948517
PMCPMC12432568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.